Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KLRA with free AI briefings, catalyst countdowns, and dilution alerts.

KLRA · Kailera Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1B Cash on Hand
29.5mo Cash Runway
Follow KLRA by email Get an email when KLRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KLRA, unsubscribe in one click. Privacy

📣 What KLRA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ribupatide Obesity With Diabetes Phase 3 · NCT07284901 Active not recruiting
KAI-7535 Obesity Phase 2 · NCT07497880 Active not recruiting
KAI-4729 Overweight or Obesity Phase 1 · NCT07924761 Not yet recruiting
KAI-9531 Healthy Volunteers Phase 1 · NCT07044401 Completed

Also used in these trials (approved or third-party drugs, not KLRA's own candidates): Oral Semaglutide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KLRA holds $1B in cash and short-term investments (as of Sep 30, 2026) and burns about $105.6M/quarter from operations, an estimated runway of 29.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 3 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KLRA files for a raise →

👥 Who Owns KLRA

Insiders 54.8% Other 5%+ holders 43.2% Institutions (167 holders) 2% Public and other holders 0%
HolderTypeShares% of sharesAs of
BAIN CAPITAL INVESTORS LLC
10% owner
Insider 26,255,581 20.22% 2026-04-20
Andrew T. Kaplan
Director, 10% owner · +38,300 options
Includes shares also reported by BAIN CAPITAL INVESTORS LLC, counted once
Insider 26,255,581 20.22% 2026-04-16
BCPE Perseus Investor, LP 5%+ holder (13D) 26,255,581 20.22% 2026-04-16
Bain Capital Life Sciences Investors, LL
10% owner
Insider 22,583,268 17.39% 2026-04-20
Adam Koppel
Director, 10% owner · +38,300 options
Includes shares also reported by Bain Capital Life Sciences Investors, LLC, counted once
Insider 22,583,268 17.39% 2026-04-16
BCLS Fund IV Investments, L.P. 5%+ holder (13D) 22,583,268 17.39% 2026-04-16
Jiangsu Hengrui Pharmaceuticals Co., Ltd
10% owner
Insider 11,511,853 8.87% 2026-06-30
RTW INVESTMENTS, LP
10% owner
Insider 10,776,820 8.30% 2026-06-30
CPP Investment Board Private Holdings (4 5%+ holder (13G) 7,304,688 5.63% 2026-06-30
Ronald C JR Renaud
CEO & President, Director · +1.12M options
Insider 38,094 0.03% 2026-06-09

Share count 129,850,481 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KLRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KLRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.